Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference. VN Giri et al. J Clin Oncol. (2017). |
2017 |
Evaluation of a Methodology for Automated Cell Counting for Streak Mode Imaging Flow Cytometry.
M Ossandon et al. Journal of Analytical & Bioanalytical Techniques. (2017). |
2017 |
A Non-Gas-Based Cryotherapy System for the Treatment of Cervical Intraepithelial Neoplasia: A Mixed-Methods Approach for Initial Development and Testing. M Cremer et al. Glob Health Sci Pract. (2017) |
2017 |
Non-alcoholic Steatofibrosis Independently Predicts Mortality in Non-alcoholic Fatty Liver Disease.
Z Younoszai et al. Hepatology Communications. (2017). |
2017 |
Characterization of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. CF Spraggs et al. Pharmacogenomics J. (2017). |
2017 |
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial (NCI-MATCH, EAY131).
Lih C-J, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM. J. Mol. Diagn. (2017) 19:313-327. |
2017 |
Development and validation of a Luminex assay for detection of a predictive biomarker for ROSTVAC-VF therapy. Lucas JL, Tacheny EA, Ferris A, Galusha M, Srivastava AK, Ganguly A, Williams PM, Sachs MC, Thurin M, Tricoli JV, Ricker W, Gildersleeve JC. PLoS One. (August 2017) 2(8):e0182739. PMID: 28771597 |
2017 |
Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.
Khoury JD, Wang W-L, Prieto VG, Medeiros LJ, Kalhor N, Hameed M, Broaddus R, Hamilton SR. Clin. Cancer Res. (August 2017) DOI: 10.1158/1078-0432.CCR-17-1597 |
2017 |
Immunotherapy biomarkers 2016: overcoming the barriers. Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH. J Immunother Cancer. 2(March 2017) 5(1):29. doi: 10.1186/s40425-017-0225-6. |
2017 |
Nanotechnology Platforms and Physiological Challenges for Cancer Therapeutics. Kim, KY. Nanomedicine's Most Cited - Volume 1: Nanomedicine in Cancer, pp. 1-15, Balogh, Lajos P. (ed.). Singapore: Pan Stanford Publishing Pte. Ltd., 2017. ISBN: 9789814745802 [invited book chapter] |
2017 |
Clinical Utility of Epstein-Barr Virus DNA Testing in the Management of Nasopharyngeal Carcinoma Patients. Kim KY, Le QT, Yom SS, Ng RHW, Chan KCA, Bratman SV, Welch JJ, Divi RL, Petryshyn RA, Conley BA. International Journal of Radiation Oncology Biology Physics (August 2017) 98(5):996-1001. |
2017 |